FDA Approves Oral PCSK9 Inhibitor for Cholesterol Reduction

Why it matters locally: Texas, with its large and diverse population, is likely to see the new oral PCSK9 inhibitor made available in healthcare facilities, offering an additional treatment option for the significant number of Texans managing hypercholesterolemia.

---

WASHINGTON – The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide) for the reduction of low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia. This medication represents the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Doctors will prescribe Lipfendra as an addition to diet and exercise regimens. The FDA's decision provides a new treatment option for individuals working to manage their cholesterol levels.